Free Trial
→ Nobody Understands Why Trump Is Invading Iran (here’s the answer) (From Banyan Hill Publishing) (Ad)tc pixel Free KALV Stock Alerts

KalVista Pharmaceuticals (KALV) Competitors

KalVista Pharmaceuticals logo
$26.71 +0.05 (+0.19%)
Closing price 04:00 PM Eastern
Extended Trading
$26.66 -0.05 (-0.18%)
As of 05:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

KALV vs. XENE, TGTX, PTCT, APLS, and APGE

Should you be buying KalVista Pharmaceuticals stock or one of its competitors? The main competitors of KalVista Pharmaceuticals include Xenon Pharmaceuticals (XENE), TG Therapeutics (TGTX), PTC Therapeutics (PTCT), Apellis Pharmaceuticals (APLS), and Apogee Therapeutics (APGE). These companies are all part of the "pharmaceutical products" industry.

How does KalVista Pharmaceuticals compare to Xenon Pharmaceuticals?

Xenon Pharmaceuticals (NASDAQ:XENE) and KalVista Pharmaceuticals (NASDAQ:KALV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

Xenon Pharmaceuticals' return on equity of -55.81% beat KalVista Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Xenon PharmaceuticalsN/A -55.81% -52.04%
KalVista Pharmaceuticals N/A -214.88%-81.87%

Xenon Pharmaceuticals has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of -0.12, meaning that its stock price is 112% less volatile than the S&P 500.

KalVista Pharmaceuticals has lower revenue, but higher earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xenon Pharmaceuticals$7.50M743.70-$345.91M-$4.36N/A
KalVista Pharmaceuticals$1.43M959.42-$109.52M-$3.95N/A

In the previous week, KalVista Pharmaceuticals had 27 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 35 mentions for KalVista Pharmaceuticals and 8 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.88 beat KalVista Pharmaceuticals' score of -0.19 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Xenon Pharmaceuticals
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
KalVista Pharmaceuticals
4 Very Positive mention(s)
5 Positive mention(s)
13 Neutral mention(s)
8 Negative mention(s)
0 Very Negative mention(s)
Neutral

95.4% of Xenon Pharmaceuticals shares are held by institutional investors. 4.1% of Xenon Pharmaceuticals shares are held by company insiders. Comparatively, 4.3% of KalVista Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Xenon Pharmaceuticals presently has a consensus target price of $73.13, suggesting a potential upside of 26.70%. KalVista Pharmaceuticals has a consensus target price of $30.60, suggesting a potential upside of 14.56%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Xenon Pharmaceuticals is more favorable than KalVista Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xenon Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
15 Buy rating(s)
2 Strong Buy rating(s)
3.00
KalVista Pharmaceuticals
1 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.22

Summary

Xenon Pharmaceuticals beats KalVista Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does KalVista Pharmaceuticals compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and KalVista Pharmaceuticals (NASDAQ:KALV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

TG Therapeutics has a net margin of 72.56% compared to KalVista Pharmaceuticals' net margin of 0.00%. TG Therapeutics' return on equity of 101.12% beat KalVista Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
TG Therapeutics72.56% 101.12% 51.88%
KalVista Pharmaceuticals N/A -214.88%-81.87%

TG Therapeutics has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of -0.12, meaning that its stock price is 112% less volatile than the S&P 500.

TG Therapeutics has higher revenue and earnings than KalVista Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TG Therapeutics$616.29M9.35$447.18M$2.7713.03
KalVista Pharmaceuticals$1.43M959.42-$109.52M-$3.95N/A

In the previous week, KalVista Pharmaceuticals had 32 more articles in the media than TG Therapeutics. MarketBeat recorded 35 mentions for KalVista Pharmaceuticals and 3 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.95 beat KalVista Pharmaceuticals' score of -0.19 indicating that TG Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TG Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
KalVista Pharmaceuticals
4 Very Positive mention(s)
5 Positive mention(s)
13 Neutral mention(s)
8 Negative mention(s)
0 Very Negative mention(s)
Neutral

58.6% of TG Therapeutics shares are held by institutional investors. 10.6% of TG Therapeutics shares are held by company insiders. Comparatively, 4.3% of KalVista Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

TG Therapeutics presently has a consensus target price of $50.00, suggesting a potential upside of 38.50%. KalVista Pharmaceuticals has a consensus target price of $30.60, suggesting a potential upside of 14.56%. Given TG Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe TG Therapeutics is more favorable than KalVista Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TG Therapeutics
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.57
KalVista Pharmaceuticals
1 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.22

Summary

TG Therapeutics beats KalVista Pharmaceuticals on 14 of the 16 factors compared between the two stocks.

How does KalVista Pharmaceuticals compare to PTC Therapeutics?

KalVista Pharmaceuticals (NASDAQ:KALV) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

KalVista Pharmaceuticals has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.

KalVista Pharmaceuticals presently has a consensus target price of $30.60, suggesting a potential upside of 14.56%. PTC Therapeutics has a consensus target price of $84.40, suggesting a potential upside of 29.77%. Given PTC Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe PTC Therapeutics is more favorable than KalVista Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
KalVista Pharmaceuticals
1 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.22
PTC Therapeutics
1 Sell rating(s)
5 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.63

PTC Therapeutics has a net margin of 39.44% compared to KalVista Pharmaceuticals' net margin of 0.00%. KalVista Pharmaceuticals' return on equity of -214.88% beat PTC Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
KalVista PharmaceuticalsN/A -214.88% -81.87%
PTC Therapeutics 39.44%-362.45%25.21%

PTC Therapeutics has higher revenue and earnings than KalVista Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KalVista Pharmaceuticals$1.43M959.42-$109.52M-$3.95N/A
PTC Therapeutics$1.73B3.12$682.64M$7.748.40

In the previous week, KalVista Pharmaceuticals had 19 more articles in the media than PTC Therapeutics. MarketBeat recorded 35 mentions for KalVista Pharmaceuticals and 16 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 0.68 beat KalVista Pharmaceuticals' score of -0.19 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
KalVista Pharmaceuticals
4 Very Positive mention(s)
5 Positive mention(s)
13 Neutral mention(s)
8 Negative mention(s)
0 Very Negative mention(s)
Neutral
PTC Therapeutics
8 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

PTC Therapeutics beats KalVista Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

How does KalVista Pharmaceuticals compare to Apellis Pharmaceuticals?

KalVista Pharmaceuticals (NASDAQ:KALV) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

KalVista Pharmaceuticals has a beta of -0.12, meaning that its share price is 112% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of -0.24, meaning that its share price is 124% less volatile than the S&P 500.

KalVista Pharmaceuticals presently has a consensus target price of $30.60, suggesting a potential upside of 14.56%. Apellis Pharmaceuticals has a consensus target price of $34.89, suggesting a potential downside of 14.83%. Given KalVista Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe KalVista Pharmaceuticals is more favorable than Apellis Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
KalVista Pharmaceuticals
1 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.22
Apellis Pharmaceuticals
2 Sell rating(s)
18 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.04

Apellis Pharmaceuticals has a net margin of 2.23% compared to KalVista Pharmaceuticals' net margin of 0.00%. Apellis Pharmaceuticals' return on equity of 8.20% beat KalVista Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
KalVista PharmaceuticalsN/A -214.88% -81.87%
Apellis Pharmaceuticals 2.23%8.20%2.38%

Apellis Pharmaceuticals has higher revenue and earnings than KalVista Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KalVista Pharmaceuticals$1.43M959.42-$109.52M-$3.95N/A
Apellis Pharmaceuticals$1.00B5.23$22.39M$0.13315.15

In the previous week, KalVista Pharmaceuticals had 26 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 35 mentions for KalVista Pharmaceuticals and 9 mentions for Apellis Pharmaceuticals. Apellis Pharmaceuticals' average media sentiment score of 1.26 beat KalVista Pharmaceuticals' score of -0.19 indicating that Apellis Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
KalVista Pharmaceuticals
4 Very Positive mention(s)
5 Positive mention(s)
13 Neutral mention(s)
8 Negative mention(s)
0 Very Negative mention(s)
Neutral
Apellis Pharmaceuticals
6 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 4.3% of KalVista Pharmaceuticals shares are held by company insiders. Comparatively, 6.5% of Apellis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Apellis Pharmaceuticals beats KalVista Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does KalVista Pharmaceuticals compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and KalVista Pharmaceuticals (NASDAQ:KALV) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

Apogee Therapeutics' return on equity of -36.77% beat KalVista Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Apogee TherapeuticsN/A -36.77% -34.87%
KalVista Pharmaceuticals N/A -214.88%-81.87%

Apogee Therapeutics currently has a consensus target price of $112.73, indicating a potential upside of 35.35%. KalVista Pharmaceuticals has a consensus target price of $30.60, indicating a potential upside of 14.56%. Given Apogee Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Apogee Therapeutics is more favorable than KalVista Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Apogee Therapeutics
1 Sell rating(s)
4 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
2.78
KalVista Pharmaceuticals
1 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.22

79.0% of Apogee Therapeutics shares are owned by institutional investors. 42.8% of Apogee Therapeutics shares are owned by insiders. Comparatively, 4.3% of KalVista Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Apogee Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of -0.12, suggesting that its stock price is 112% less volatile than the S&P 500.

In the previous week, KalVista Pharmaceuticals had 28 more articles in the media than Apogee Therapeutics. MarketBeat recorded 35 mentions for KalVista Pharmaceuticals and 7 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 0.90 beat KalVista Pharmaceuticals' score of -0.19 indicating that Apogee Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Apogee Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
KalVista Pharmaceuticals
4 Very Positive mention(s)
5 Positive mention(s)
13 Neutral mention(s)
8 Negative mention(s)
0 Very Negative mention(s)
Neutral

KalVista Pharmaceuticals has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apogee TherapeuticsN/AN/A-$255.84M-$4.22N/A
KalVista Pharmaceuticals$1.43M959.42-$109.52M-$3.95N/A

Summary

Apogee Therapeutics beats KalVista Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get KalVista Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KALV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KALV vs. The Competition

Export
MetricKalVista PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.37B$3.10B$6.25B$11.87B
Dividend YieldN/A1.91%2.73%5.21%
P/E Ratio-6.7618.3729.0428.47
Price / Sales959.42281.30476.6160.92
Price / CashN/A50.4327.6236.52
Price / Book9.864.339.676.67
Net Income-$109.52M$72.19M$3.55B$332.53M
7 Day Performance38.83%2.03%1.70%2.01%
1 Month Performance34.22%6.42%5.62%9.19%
1 Year Performance103.89%37.73%34.41%39.59%

KalVista Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KALV
KalVista Pharmaceuticals
1.4482 of 5 stars		$26.71
+0.2%		$30.60
+14.6%		N/A$1.37B$1.43MN/A100
XENE
Xenon Pharmaceuticals
3.2125 of 5 stars		$57.40
+2.3%		$73.13
+27.4%		N/A$5.42B$7.50MN/A210
TGTX
TG Therapeutics
3.9609 of 5 stars		$35.71
+5.5%		$50.00
+40.0%		N/A$5.41B$616.29M12.89290
PTCT
PTC Therapeutics
3.8162 of 5 stars		$65.49
+0.5%		$84.40
+28.9%		N/A$5.40B$1.73B8.461,410
APLS
Apellis Pharmaceuticals
1.9609 of 5 stars		$40.97
+0.0%		$34.89
-14.8%		N/A$5.24B$1.00B315.18770

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:KALV) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel